LENZ Therapeutics Inc. (LENZ)
NASDAQ: LENZHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LENZ stock chart
Technical analysisKey statistics
All statistics- Market cap
- $93.16M
- EPS (TTM)
- -$4.53
- Dividend yield
- None
- Ex-dividend date
- Mar 22, 2024
- 52-week range
- 2.80 – 32.13
- Day range
- 2.82 – 3.44
- Volume / Avg
- 951.16K / 892.30K
- Beta
- —
- Shares outstanding
- 31.42M
52-week range
LENZ stock today
On Nov 20, LENZ ended the session at $2.97, shedding $0.375 (11.23%), versus the S&P 500's 3.70% decline. Shares are 90.8% below their 52-week high of $32.13, set on Nov 24, 2025 and 5.9% above the 52-week low of $2.80, near the bottom of the past year's range. LENZ is down 81.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 90.0%.
LENZ Therapeutics has posted a net loss over the last twelve months (EPS of -$4.53), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About LENZ Therapeutics
Company profileLENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Evert B. Schimmelpennink
- Headquarters
- Solana Beach, CA
- Employees
- 40
- IPO year
- 2021
- Website
- lenz-tx.com
Financial highlights
Full financialsIn fiscal 2025, LENZ Therapeutics generated $19.1 million in revenue, up 0.0% from fiscal 2024. LENZ Therapeutics reported a net loss of $82.1 million, compared with a loss of $49.8 million a year earlier. Gross margin was 97.8% and operating margin -477.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $19.09M | $0 | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-82.13M | $-49.77M | $-69.97M | $-101.05M | $-70.76M |
| EPS (diluted) | $-2.85 | $-2.34 | $-35.71 | $-1.84 | $-2.45 |
Analyst forecast
ForecastConsensus (6 analysts)
none
Avg. price target
$14.83+400.17%
- Strong buy 0
- Buy 4
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 28, 2026
- EPS actual vs est.
- $-0.99 vs $-0.97
- Surprise
- -2.06%
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $7.21
- Ex-dividend date
- Mar 22, 2024
LENZ news
All LENZ news- LENZ (LENZ) Q3 2026 Earnings Call TranscriptNasdaq
- LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO SuccessionGlobeNewswire
- Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseNasdaqREGN, LENZ
LENZ Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OTLKOutlook Therapeutics Inc. | 0.39 | -2.74% | $94.94M | vs LENZ |
| VYGRVoyager Therapeutics Inc. | 1.53 | -4.97% | $95.21M | vs LENZ |
| IPHAInnate Pharma S.A. ADS | 0.8634 | -8.14% | $96.44M | vs LENZ |
| ZURAZura Bio Limited Class A | 0.9305 | -2.30% | $89.63M | vs LENZ |
| MOLNMolecular Partners AG ADR | 2.53 | -5.25% | $96.80M | vs LENZ |
| CRDLCardiol Therapeutics Inc. Class A | 0.8626 | -2.28% | $110.14M | vs LENZ |
| BDTXBlack Diamond Therapeutics Inc. | 1.31 | -5.76% | $75.28M | vs LENZ |
| FATEFate Therapeutics Inc. | 0.919 | -9.01% | $111.82M | vs LENZ |
Indexes, lists and sector
LENZ Therapeutics stock FAQ
What is LENZ Therapeutics's stock price today?
LENZ last traded at $2.97 as of Nov 20, 4:00 PM EST, down 11.23% on the day. Prices are delayed at least 15 minutes.
Does LENZ Therapeutics pay a dividend?
Yes. LENZ Therapeutics pays $0.00 per share annually. The most recent dividend of $7.21 had an ex-dividend date of Mar 22, 2024.
Who is LENZ Therapeutics's CEO?
Mr. Evert B. Schimmelpennink is the chief executive officer of LENZ Therapeutics Inc., which has about 40 employees.
Has LENZ ever split its stock?
Yes. The most recent LENZ stock split was a 1-for-7 split on Mar 22, 2024.
What is the LENZ 52-week high?
The 52-week high for LENZ is $32.13 and the 52-week low is $2.80. The stock is currently 90.8% below its high.